Moreover, the combination of an ERβ agonist with TMZ has been found to be a good method of inhibiting glial tumor growth, probably through the effect of the ERβ agonist on inhibiting the activity of the PI3K/AKT/MTOR pathway, which contributes to the protection of tumor cells from TMZ-induced cytotoxicity [59]. Here, ESR2 is linked to neoplasm.